OSIGRAFT

This brand name is authorized in Austria, Estonia, Lithuania

Active ingredients

The drug OSIGRAFT contains one active pharmaceutical ingredient (API):

1 Eptotermin alfa UNII IT063R5MY0 - EPTOTERMIN ALFA

Eptotermin alfa, the active substance, initiates bone formation through the induction of cellular differentiation in mesenchymal cells, which are recruited to the implant site from bone marrow, periosteum and muscle. Once bound at the cell surface, the active substance induces a cascade of cellular events leading to the formation of chondroblasts and osteoblasts, which play a key role in the bone formation process. Read about Eptotermin alfa

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
OSIGRAFT Powder for suspension for implantation	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
M05BC02	Eptotermin alfa	M Musculo-skeletal system → M05 Drugs for treatment of bone diseases → M05B Drugs affecting bone structure and mineralization → M05BC Bone morphogenetic proteins
Discover more medicines within M05BC02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1202577
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1030362